| Dermatitis |
1 |
1 |
| Herpes Zoster |
0 |
0.78 |
| Adolescent Medicine |
0 |
0.47 |
| Atopic Dermatitis |
0 |
1 |
| Cardiovascular Risk Management |
0 |
0.42 |
| Body Mass Index |
0 |
0.31 |
| Clinical Research |
0 |
0.31 |
| Herpes Zoster Vaccine |
0 |
0.31 |
| Thromboembolism |
0 |
0.28 |
| Venous Thromboembolism (VTE) |
0 |
0.27 |
| Healthcare and Medical Technology |
0 |
0.25 |
| Vaccines |
0 |
0.25 |
| Skin Cancer |
0 |
0.24 |
| Nonmelanoma Skin Cancer |
0 |
0.22 |
| Topical Corticosteroid |
0 |
0.22 |
| Cancer |
0 |
0.16 |
| Child |
0 |
0.16 |
| Connecticut |
0 |
0.16 |
| Corticosteroids |
0 |
0.16 |
| Grant |
0 |
0.16 |
| Opportunistic Infection |
0 |
0.16 |
| Refractory |
0 |
0.16 |
| Tobacco Use |
0 |
0.16 |
| UK Site Content |
0 |
0.16 |
| Hypertension |
0 |
0.12 |
| Tobacco Cessation |
0 |
0.12 |
| Tuberculosis |
0 |
0.12 |